Zydus Cadila gets USFDA nod for potassium chloride tablets

Pharmaceutical manufacturer Zydus Cadila said it received final approval from the US Food and Drug Administration for the sales of Potassium Chloride extended-release tablets for the treatment of various diseases such as prolonged diarrhoea and vomiting, hormone problems such as hyperaldosteronism and diuresis.

The tablet, sold under the brand names Klor-Con, K-Dur and Micro-K, is a mineral supplement used to treat or prevent low amounts of potassium in the blood.

The drug will be sold in doses of 600 mg and 750 mg.

With the latest nod, the company has so far received 254 approvals and filed over 350 applications for sales of various drug products.

Headquartered in Ahmedabad, Zydus Cadila has manufacturing sites and research facilities across Gujarat, Maharashtra, Goa, Himachal Pradesh and Sikkim and even in the United States and Brazil.